secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001493152-24-031862
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics appoints Drs. Zeiher and Crombez to Board of Directors
--------------------------------------------------------------------------

- Bernhardt G. Zeiher, MD appointed as Class 1 director; Eric Crombez, MD as Class 2 director; both independent.
- Zeiher is former CMO of Astellas Pharma with 20+ years of drug development; Crombez is CMO of Ultragenyx and FDA advisory committee member.
- Each director receives $50,000 annual cash retainer and $55,000 one-time RSAs with one-year vesting.
- Appointments effective August 8, 2024 (Zeiher) and August 12, 2024 (Crombez).
- Additions come as Abeona focuses on pz-cel gene therapy for RDEB and pipeline expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/0001493152-24-031862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer